目的了解中国血液病患者中性粒细胞缺乏（粒缺）伴发热的发生率、临床和微生物学特征及危险因素。方法前瞻性研究2014年10月20日至2015年3月20日来自全国11家血液病中心发生粒缺伴发热的连续血液病患者发热情况及危险性因素。结果1 139...目的了解中国血液病患者中性粒细胞缺乏（粒缺）伴发热的发生率、临床和微生物学特征及危险因素。方法前瞻性研究2014年10月20日至2015年3月20日来自全国11家血液病中心发生粒缺伴发热的连续血液病患者发热情况及危险性因素。结果1 139例患者共发生784例次粒缺伴发热，粒缺持续21 d时发热的累积发生率为81.9%。多因素分析显示中心静脉置管（P〈0.001，HR= 3.407，95% CI 2.276-4.496 ）、胃肠道黏膜炎（P〈0.001，HR=10.548, 95% CI 3.245-28.576）、既往90 d内暴露于广谱抗生素（P〈0.001，HR=3.582，95% CI 2.387-5.770）和粒缺持续时间〉7 d （P〈0.001，HR= 4.194，95% CI 2.572-5.618）是粒缺伴发热的危险因素。无任何危险因素、具备1项、2项、3-4项危险因素患者发热的累计发生率依次增加（35.4%、69.2%、86.1%及95.6%，P〈0.001）。784例次粒缺伴发热中，不明原因发热253例次（32.3%），临床证实的感染429例次（54.7%），微生物学证实的感染102例次（13.0%）。最常见的感染部位依次为肺（388例次，49.5%）、上呼吸道（159例次，16.0%）、肛周组织（77例次，9.8%）、血流（60例次，7.7%）。最常见的病原菌为革兰阴性菌（44.54%），其次为革兰阳性菌（37.99%）和真菌（17.47%）。发热与未发热患者相比，两组之间总体病死率差异无统计学意义（9.2%对4.8%，P=0.099）。多因素分析显示年龄〉40岁（P=0.047 ，HR=5.000 ，95% CI 0.853-28.013 ）、血流动力学不稳（P=0.001，HR=13.185, 95% CI 2.983-54.915）、既往耐药菌的定植或感染（P=0.005 ，HR=28.734， 95% CI 2.921-313.744）、血流感染（P=0.038 ，HR=9.715, 95% CI 1.110-81.969）和肺部感染（P=0.031， HR=25.905, 95% CI 1.381-507.006）是与总体死亡相关的危险因素。展开更多
AIM: To investigate the correlation between uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) gene polymorphisms and irinotecan-associated side effects and parameters of drug efficacy in patients with metastat...AIM: To investigate the correlation between uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) gene polymorphisms and irinotecan-associated side effects and parameters of drug efficacy in patients with metastatic colorectal cancer (mCRC) receiving a low-dose weekly irinotecan chemotherapeutic regimen. METHODS: Genotypes were retrospectively evaluated by gene scan analysis on the ABI 310 sequencer of the TATAA box in the promoter region of the UGT1A1 gene in blood samples from 105 patients who had received 1st line irinotecan-based chemotherapy for mCRC. RESULTS: The distribution of the genotypes was as follows: wild type genotype (WT) (6/6 ) 39.0%, heterozygous genotype (6/7) 49.5%, and homozygous genotype (7/7) 9.5%. The overall response rate (OR) was similar between patients carrying the (6/7, 7/7) or the WT genotype (6/6) (44.3% vs 43.2%, P = 0.75). Neither time to progression [(TTP) 8.1 vs 8.2 mo, P = 0.97] nor overall survival [(OS) 21.2 vs 18.9 mo, P = 0.73] differed significantly in patients who carried the(6/6) when compared to the (6/7, 7/7) genotype. No significant differences in toxicity were observed: Grade 3 and 4 delayed diarrhoea [(6/7, 7/7) vs (6/6); 13.0% vs 6.2%, P =0.08], treatment delays [(6/7, 7/7) vs (6/6); 25.1% vs 19.3%, P = 0.24] or dose reductions [(6/7, 7/7) vs (6/6); 21.5% vs 27.2%, P = 0.07].CONCLUSION: This analysis demonstrates the non-significant influence of the UGT1A1 gene polymorphism on efficacy and rate of irinotecan-associated toxicity in mCRC patients receiving low-dose irinotecan based chemotherapy.展开更多
中性粒细胞缺乏伴发热是血液科医生面临的常见问题,也是棘手问题。由于此类患者免疫功能低下,感染的症状和体征常不典型、不明显,病原菌和感染灶也常不明确,感染相关死亡率高。造血系统恶性肿瘤患者中性粒细胞缺乏伴感染相关死亡率高达1...中性粒细胞缺乏伴发热是血液科医生面临的常见问题,也是棘手问题。由于此类患者免疫功能低下,感染的症状和体征常不典型、不明显,病原菌和感染灶也常不明确,感染相关死亡率高。造血系统恶性肿瘤患者中性粒细胞缺乏伴感染相关死亡率高达11%,鉴于此,美国感染病学会（Infectious Diseases Society of America,IDSA）于1997年首次发表了中性粒细胞缺乏伴发热患者治疗指南[1],并于2002年[2]和2010年[3]进行了两次更新。展开更多
文摘目的了解中国血液病患者中性粒细胞缺乏（粒缺）伴发热的发生率、临床和微生物学特征及危险因素。方法前瞻性研究2014年10月20日至2015年3月20日来自全国11家血液病中心发生粒缺伴发热的连续血液病患者发热情况及危险性因素。结果1 139例患者共发生784例次粒缺伴发热，粒缺持续21 d时发热的累积发生率为81.9%。多因素分析显示中心静脉置管（P〈0.001，HR= 3.407，95% CI 2.276-4.496 ）、胃肠道黏膜炎（P〈0.001，HR=10.548, 95% CI 3.245-28.576）、既往90 d内暴露于广谱抗生素（P〈0.001，HR=3.582，95% CI 2.387-5.770）和粒缺持续时间〉7 d （P〈0.001，HR= 4.194，95% CI 2.572-5.618）是粒缺伴发热的危险因素。无任何危险因素、具备1项、2项、3-4项危险因素患者发热的累计发生率依次增加（35.4%、69.2%、86.1%及95.6%，P〈0.001）。784例次粒缺伴发热中，不明原因发热253例次（32.3%），临床证实的感染429例次（54.7%），微生物学证实的感染102例次（13.0%）。最常见的感染部位依次为肺（388例次，49.5%）、上呼吸道（159例次，16.0%）、肛周组织（77例次，9.8%）、血流（60例次，7.7%）。最常见的病原菌为革兰阴性菌（44.54%），其次为革兰阳性菌（37.99%）和真菌（17.47%）。发热与未发热患者相比，两组之间总体病死率差异无统计学意义（9.2%对4.8%，P=0.099）。多因素分析显示年龄〉40岁（P=0.047 ，HR=5.000 ，95% CI 0.853-28.013 ）、血流动力学不稳（P=0.001，HR=13.185, 95% CI 2.983-54.915）、既往耐药菌的定植或感染（P=0.005 ，HR=28.734， 95% CI 2.921-313.744）、血流感染（P=0.038 ，HR=9.715, 95% CI 1.110-81.969）和肺部感染（P=0.031， HR=25.905, 95% CI 1.381-507.006）是与总体死亡相关的危险因素。
文摘AIM: To investigate the correlation between uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) gene polymorphisms and irinotecan-associated side effects and parameters of drug efficacy in patients with metastatic colorectal cancer (mCRC) receiving a low-dose weekly irinotecan chemotherapeutic regimen. METHODS: Genotypes were retrospectively evaluated by gene scan analysis on the ABI 310 sequencer of the TATAA box in the promoter region of the UGT1A1 gene in blood samples from 105 patients who had received 1st line irinotecan-based chemotherapy for mCRC. RESULTS: The distribution of the genotypes was as follows: wild type genotype (WT) (6/6 ) 39.0%, heterozygous genotype (6/7) 49.5%, and homozygous genotype (7/7) 9.5%. The overall response rate (OR) was similar between patients carrying the (6/7, 7/7) or the WT genotype (6/6) (44.3% vs 43.2%, P = 0.75). Neither time to progression [(TTP) 8.1 vs 8.2 mo, P = 0.97] nor overall survival [(OS) 21.2 vs 18.9 mo, P = 0.73] differed significantly in patients who carried the(6/6) when compared to the (6/7, 7/7) genotype. No significant differences in toxicity were observed: Grade 3 and 4 delayed diarrhoea [(6/7, 7/7) vs (6/6); 13.0% vs 6.2%, P =0.08], treatment delays [(6/7, 7/7) vs (6/6); 25.1% vs 19.3%, P = 0.24] or dose reductions [(6/7, 7/7) vs (6/6); 21.5% vs 27.2%, P = 0.07].CONCLUSION: This analysis demonstrates the non-significant influence of the UGT1A1 gene polymorphism on efficacy and rate of irinotecan-associated toxicity in mCRC patients receiving low-dose irinotecan based chemotherapy.
文摘中性粒细胞缺乏伴发热是血液科医生面临的常见问题,也是棘手问题。由于此类患者免疫功能低下,感染的症状和体征常不典型、不明显,病原菌和感染灶也常不明确,感染相关死亡率高。造血系统恶性肿瘤患者中性粒细胞缺乏伴感染相关死亡率高达11%,鉴于此,美国感染病学会（Infectious Diseases Society of America,IDSA）于1997年首次发表了中性粒细胞缺乏伴发热患者治疗指南[1],并于2002年[2]和2010年[3]进行了两次更新。
